KPV peptide: what it is and its status under the HHS policy

KPV is a three-amino-acid peptide (lysine, proline, valine) cut from the end of the hormone alpha-MSH, studied for inflammation almost entirely in cells and preclinical models. FDA has found no human exposure data for it. Under HHS's interim policy, licensed pharmacies may compound KPV acetate in topical and oral forms only; injectable KPV is not covered (HHS policy, archived copy).

Below: what KPV is, what the research shows and does not show, exactly which forms the HHS policy covers, the extra condition on oral products, and what that means if a program offers it. Policy facts were checked on 30 October 2026. Compounded drugs are not FDA-approved, and the policy is interim.

What KPV is

Alpha-MSH (alpha-melanocyte-stimulating hormone) is a 13-amino-acid hormone with two known jobs: it darkens skin pigment and it damps down inflammation. KPV is its last three amino acids, positions 11 to 13. Researchers became interested in the fragment because it seemed to keep the anti-inflammatory effect without the tanning effect.

A 2008 review in Endocrine Reviews put it this way: "One obstacle limiting the use of alpha-MSH in inflammatory disorders is its pigmentary effect" and so "the C-terminal tripeptide of alpha-MSH, KPV, has been delineated as an alternative for antiinflammatory therapy" (Brzoska 2008, PubMed 18612139). The first report of its anti-inflammatory activity dates to 1989 (Hiltz and Lipton 1989, PubMed 2550304).

What the research shows

Almost all KPV research is preclinical: human cells in a dish, tissue samples, and preclinical models of colitis and skin inflammation.

The Dalmasso team found that "Nanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways" and concluded that "KPV is transported into cells by PepT1 and might be a new therapeutic agent for IBD" (Dalmasso 2008, PubMed 18061177). "Might be" is the honest phrase: no trial has tested that in people with inflammatory bowel disease.

The skin study matters for topical products. Its authors reported that "KPV permeation was less than detectable levels" by passive diffusion through human skin (Pawar 2017, PubMed 28343991). That was a lab test on skin samples, not a study of a finished cream on a patient, but it shows that putting KPV on skin does not mean it gets in.

What is known in people

Very little. FDA's compounding page states: "FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration" (FDA). We searched ClinicalTrials.gov on 30 October 2026 and found no registered KPV trial, and our PubMed search found no published human trial.

HHS justified including KPV mainly on use and quality grounds, not on human trial results. It cites documented compounding use, "including substantial single-ingredient use of the kind this policy covers", and newer quality testing of the acetate form (HHS policy, archived copy). So nobody knows yet whether KPV helps any condition in people, what side effects it causes, or how it interacts with other medicines. A clinician prescribing it is working from preclinical data.

KPV under the HHS policy: which routes are covered

We read the policy document itself (HHS's PDF, through an archived copy because hhs.gov blocks automated readers). Appendix A lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Appendix B sets the route for each. For KPV it states that "enforcement discretion for KPV acetate is appropriate for topical and oral dosage forms" made from an ingredient with a qualifying certificate of analysis (HHS policy, archived copy).

The single-ingredient rule reads: "The compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A" (HHS policy, archived copy). Multi-peptide "recovery" blends that include KPV fall outside it, whatever the label says.

The policy itself is not approval. The Federal Register notice states that "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed", and that HHS "may revisit application of this interim policy (in whole or in part)" if a safety or quality problem appears (Federal Register). See our HHS peptide policy guide for every condition.

The oral KPV condition

Oral peptides carry an extra requirement. The policy says: "Achieving adequate oral bioavailability of peptides is inherently difficult and complex" and that "the compounder is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans" (HHS policy, archived copy).

We found no published human data on how much oral KPV reaches the bloodstream. The PepT1 transporter work suggests a route into gut cells, but that comes from cell and preclinical studies. If a program offers oral KPV, ask which data its pharmacy holds to meet this condition. The same rule applies to oral BPC-157; see oral BPC-157 vs injection.

Who offers prescription KPV

As of 30 October 2026, none of the programs we track lists KPV. Superpower's peptides page lists BPC-157, TB-500, MOTS-c, Epitalon, oral BPC and a Semax nasal spray, with no KPV (Superpower). We will add KPV programs to the price table when a licensed program publishes a price. Until then, a KPV offer from a site that does not require a clinician's evaluation is a research-use-only product, not a prescription; see research vs prescription peptides and compounded peptide safety.

FAQ

What is the KPV peptide?

KPV is a tripeptide made of lysine, proline and valine, the final three amino acids of the hormone alpha-MSH. Researchers study it because it appears to keep alpha-MSH's anti-inflammatory activity without darkening skin. Nearly all the evidence comes from cell and preclinical studies of gut and skin inflammation. KPV is not FDA-approved for any use.

Is KPV covered by the HHS peptide policy?

Partly. HHS's interim policy, dated 28 October 2026, covers KPV acetate compounded by a licensed 503A pharmacy in topical and oral forms, on a patient-specific prescription. Injectable KPV and blends that combine KPV with other peptides are not covered. The policy is not FDA approval and can be withdrawn. Checked 30 October 2026.

Is injectable KPV legal?

Injectable KPV is outside the HHS interim policy, because the policy's appendix lists only topical and oral dosage forms for KPV acetate. A pharmacy compounding injectable KPV would not have the policy's enforcement discretion. Research-use-only injectable KPV sold online is not a prescription drug at all. State pharmacy rules add their own limits.

Does KPV work for gut inflammation?

Unknown in people. Cell studies and preclinical colitis models found reduced inflammatory signaling, and one team proposed KPV as a possible treatment for inflammatory bowel disease. No human trial has tested it, and FDA says it found no human exposure data. Anyone with IBD should stay on proven treatment and discuss KPV with their gastroenterologist.

What are the side effects of KPV?

Nobody knows from controlled data. FDA reported no human exposure data on KPV by any route, and we found no registered human trial on ClinicalTrials.gov. HHS described FDA's safety concern as an absence of information, not an observed harm. That means side effects, interactions and long-term risks in people have not been measured.

Does topical KPV absorb through skin?

Limited evidence suggests plain KPV passes through intact skin poorly. A lab study on donated human skin found permeation below detectable levels by passive diffusion, with microneedles and a mild electric current needed to increase delivery. A compounded cream could behave differently, so ask the pharmacy what testing supports its formulation.

Compare licensed programs for the HHS-covered peptides on our best peptide programs page, or see every listed plan on the price table.